GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » PS Ratio

Evolus (Evolus) PS Ratio : 3.45 (As of May. 21, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evolus PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Evolus's share price is $13.16. Evolus's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $3.82. Hence, Evolus's PS Ratio for today is 3.45.

The historical rank and industry rank for Evolus's PS Ratio or its related term are showing as below:

EOLS' s PS Ratio Range Over the Past 10 Years
Min: 1.78   Med: 3.62   Max: 226.19
Current: 3.51

During the past 9 years, Evolus's highest PS Ratio was 226.19. The lowest was 1.78. And the median was 3.62.

EOLS's PS Ratio is ranked worse than
68.66% of 1002 companies
in the Drug Manufacturers industry
Industry Median: 2.215 vs EOLS: 3.51

Evolus's Revenue per Sharefor the three months ended in Mar. 2024 was $1.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $3.82.

During the past 12 months, the average Revenue per Share Growth Rate of Evolus was 37.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 28.40% per year.

During the past 9 years, Evolus's highest 3-Year average Revenue per Share Growth Rate was 28.90% per year. The lowest was 28.40% per year. And the median was 28.65% per year.

Back to Basics: PS Ratio


Evolus PS Ratio Historical Data

The historical data trend for Evolus's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus PS Ratio Chart

Evolus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only 9.84 2.00 3.25 2.83 2.97

Evolus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.04 2.44 2.80 2.97 3.67

Competitive Comparison of Evolus's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's PS Ratio distribution charts can be found below:

* The bar in red indicates where Evolus's PS Ratio falls into.



Evolus PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Evolus's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=13.16/3.818
=3.45

Evolus's Share Price of today is $13.16.
Evolus's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Evolus  (NAS:EOLS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Evolus PS Ratio Related Terms

Thank you for viewing the detailed overview of Evolus's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolus (Evolus) Business Description

Traded in Other Exchanges
Address
520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Executives
David Moatazedi director, officer: See Remarks C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Medytox Inc. 10 percent owner 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Sandra Beaver officer: Chief Financial Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar officer: See Remarks 1618 STATION STREET, VANCOUVER A1 V6A 1B6
Vikram Malik director 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Alphaeon 1 Llc 10 percent owner 4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman director 8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank director C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail officer: See Remarks 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
David N Gill director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Crystal Muilenburg officer: Chief Marketing Officer 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart director 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Michael M. Jafar officer: Chief Marketing Officer 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614